Recognise clinically important loss of strength and physical reserve, separate chronic sarcopenia from acute disease and focal neurology, and rebuild function through progressive resistance, activity, nutrition and cause treatment.
Clarify whether the problem is chronic loss of reserve or an acute change. Ask baseline transfers, stairs, walking distance, shopping, carrying, falls and recovery after recent illness. Collateral may reveal that a person previously walked outdoors but has stayed in bed since admission. Sudden or asymmetric change requires acute neurological or medical investigation, not a sarcopenia label.
EWGSOP2 places low muscle strength at the centre: low strength makes sarcopenia probable, low muscle quantity or quality confirms it, and low physical performance indicates severe sarcopenia. This sequence is clinically useful because strength predicts function and can be tested at the bedside, while muscle mass measurement may require specialist equipment.
Use SARC-F to case-find where appropriate, but do not let a reassuring questionnaire override observed difficulty rising, repeated falls or evident wasting. Measure handgrip with a calibrated dynamometer when feasible, or use a five-times chair-rise test with arms crossed if safe. Record protocol, chair height, pain and encouragement. Inability to attempt is itself important but may reflect pain or balance as well as strength.
Motor-unit loss, anabolic resistance, hormonal change, mitochondrial dysfunction and reduced activity progressively reduce muscle quality and force.
Inflammation, cancer, cardiac, respiratory, renal, liver, endocrine and neurological disease accelerate catabolism and reduce activity or intake.
Dysphagia, dentition, depression, poverty, cognitive impairment, drug effects and care dependence reduce energy and protein available for muscle maintenance.
Bed rest, delirium, hospital routines, pain and immobilising equipment cause rapid loss of strength, orthostatic tolerance and task practice.
Older muscle has a blunted protein-synthesis response to dietary amino acids and low-intensity activity, so adequate protein must accompany a sufficient resistance stimulus.
Loss and incomplete reinnervation of motor units reduces power and rapid corrective responses before limb mass visibly declines.
Acute and chronic inflammatory cytokines increase protein breakdown and suppress appetite, linking disease severity to muscle loss.
Inactivity reduces strength, aerobic capacity and confidence, making ADLs harder and promoting still less activity. The change can become clinically important during even a brief acute admission.
Reduced strength and power make minor illness or a short admission cross the threshold from independence to dependency.
Low handgrip or poor chair-rise strength in the appropriate clinical context makes sarcopenia probable.
Low strength plus low appendicular muscle quantity or quality confirms the diagnosis.
Low strength and muscle quantity accompanied by slow gait or low SPPB indicates severe functional disease.
A sharp decline after bed rest or illness with global low endurance and no focal signs suggests disuse but still requires cause review.
Rapid proximal weakness, pain, rash or dark urine with CK concern is not simple age-related sarcopenia.
Dysphagia, weak cough or respiratory decline requires urgent neuromuscular and airway assessment.
Frailty is broader vulnerability across systems; sarcopenia is a muscle disorder and can contribute without being identical.
Stroke, myelopathy, neuropathy, Parkinsonism and motor-neurone disease produce pattern-specific signs requiring localisation. Examination localises these disorders before exercise is progressed.
Proximal weakness with CK, rash, pain, thyroid, adrenal or medication clues needs targeted investigation. CK and targeted biochemical testing help distinguish these treatable mechanisms.
Weight and muscle loss from disease or inadequate intake overlap with sarcopenia but demand cause-specific treatment.
Apparent weakness may reflect arthritis, orthostatic symptoms, breathlessness or fear preventing maximal performance. This can occur despite relatively preserved muscle mass and contractile function.
Low power impairs rising and protective stepping, increasing falls and fracture consequences. The resulting injury can accelerate further muscle and functional loss.
Difficulty transferring, bathing, toileting and shopping can persist after the acute disease resolves. Timely rehabilitation can determine whether that new dependency becomes permanent.
Immobility increases tissue pressure, venous stasis, constipation and respiratory complications. Atelectasis, secretion retention and infection risk also rise as mobility falls.
Low reserve increases operative, chemotherapy and admission complications and prolongs recovery. This vulnerability should modify support and monitoring, not exclude beneficial treatment automatically.
Unrecovered function can exceed household support and lead to crisis placement or unsafe lifting. Early equipment, rehabilitation and support planning can prevent an avoidable crisis.
A person can have low force despite an apparently preserved body size, and strength better captures immediate function.
Every unnecessary day without standing and walking can deepen disability and should prompt a mobility plan.
Extra protein alone cannot recreate power without progressive muscle loading.
Poor chair rise can reflect pain, balance, cognition or breathlessness and requires examination.
Food preparation, stairs, transport and carer capacity can decide whether a sound prescription is delivered.
Age or frailty should modify dose and supervision, not become a reason to omit progressive rehabilitation.
Using sarcopenia as a synonym for frailty or low body weight.
Attributing sudden asymmetric weakness to deconditioning.
Relying on SARC-F alone despite clear clinical weakness.
Measuring gait without recording aid, pain, cueing or protocol.
Giving high-protein advice without renal, swallowing, energy and food-access assessment.
Offering supplements without progressive resistance training.
Equating a physiotherapy referral with an exercise dose actually delivered.
Allowing continence devices, monitors or ward routines to immobilise a person unnecessarily.
Your practice draft is saved in this browser.
An 81-year-old has progressive difficulty rising from a chair, low grip strength and a low appendicular lean mass on DXA, but gait speed remains preserved. Which interpretation is most accurate?
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Confirm reduced muscle quantity when it affects diagnostic or treatment certainty. DXA-derived appendicular lean mass is a reference clinical method; validated bioelectrical impedance is more accessible but changes with hydration and device equations. CT or MRI muscle measures may be available from existing imaging but are not routine screening. Avoid diagnosing from body weight or calf appearance alone.
Assess physical performance with gait speed, SPPB or Timed Up and Go, using consistent aid and conditions. Also examine muscle pattern, tone, reflexes, sensation, joints and cardiorespiratory reserve. Screen cognition, mood, vision, orthostatic symptoms and fear. A performance score describes current function; it does not identify whether the limiting mechanism is muscle, pain, breathlessness or comprehension.
Investigate secondary causes from history and examination. Common first tests include FBC, renal and electrolytes, liver, CRP or ESR when inflammation is suspected, thyroid, glucose or HbA1c, calcium and vitamin D context. Add CK for myalgia or rapid proximal weakness, B12 for neuropathy, coeliac or malignancy tests for weight loss and organ-specific assessment. Review glucocorticoids, sedatives and interacting medicines.
Exercise is the core treatment. Use progressive resistance training for major muscle groups two or more times weekly, starting at a safe achievable load and increasing resistance or repetitions as adaptation occurs. Add challenging balance, gait and task practice and aerobic activity matched to capacity. After acute illness, short frequent mobilisation may begin the route but should progress beyond low-load movement.
Nutrition supports, rather than substitutes for, training. Estimate energy and protein with a dietitian when frailty, weight loss or organ disease is present. Many older adults require roughly 1.0 to 1.2 g protein/kg/day, and 1.2 to 1.5 g/kg/day may be considered during acute or chronic illness when clinically appropriate. Distribute high-quality protein across meals; address dentition, swallowing, shopping, cooking and assistance.
In advanced CKD, severe liver disease or metabolic instability, generic high-protein advice can be harmful or infeasible; agree targets with the relevant dietitian and team. Correct vitamin D deficiency and other micronutrient deficiency but do not present supplementation as a stand-alone muscle treatment. Oral nutritional supplements are used when food-first measures cannot meet assessed needs, with intake and weight monitored.
Hospital practice can either preserve or remove function. Encourage normal clothing, meals in a chair, independent washing and toileting, safe corridor walking and access to glasses, hearing aids and walking aid. Remove catheters and monitors when no longer needed and manage pain, delirium, posture and sleep. Set a mobility plan visible to the team and carers.
Review outcomes that matter: chair rise, walking range, falls, ADLs, fatigue and participation, together with weight and intake. If progress stalls, reconsider disease activity, exercise dose, pain, mood, adherence, transport and carer feasibility. A discharge destination should not become permanent merely because rehabilitation was delayed.